This article interpreted the recommendations of ASCO guideline on the use of poly (ADP-ribose) polymerase inhibitor (PARPi) for management of epithelial ovarian, tubal or primary peritoneal cancer. This systematic review-based guideline finally identified 17 eligible trials. Guideline recommendations were based on the review of evidence, US Food and Drug Administration approvals, and expert consensus when relevant evidence was lacking. The guideline pertains to patients who are PARPi na?ve. Treatment recommendations, evidence quality and strength of recommendations were provided on the aspects mainly focused on repeating PARPi, newly diagnosed ovarian cancer, second-line and beyond maintenance treatment of recurrent ovarian cancer as well as PARPi in combination therapy. The guideline also provided recommendations on the management of adverse events, and elaborated communications between patient and clinician, limitations of the research and future perspectives.